JP2026053355A5 - - Google Patents

Info

Publication number
JP2026053355A5
JP2026053355A5 JP2025217417A JP2025217417A JP2026053355A5 JP 2026053355 A5 JP2026053355 A5 JP 2026053355A5 JP 2025217417 A JP2025217417 A JP 2025217417A JP 2025217417 A JP2025217417 A JP 2025217417A JP 2026053355 A5 JP2026053355 A5 JP 2026053355A5
Authority
JP
Japan
Prior art keywords
conjugate
fab
amino acid
seq
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2025217417A
Other languages
English (en)
Japanese (ja)
Other versions
JP2026053355A (ja
Filing date
Publication date
Priority claimed from PCT/US2021/023381 external-priority patent/WO2021194913A1/en
Application filed filed Critical
Publication of JP2026053355A publication Critical patent/JP2026053355A/ja
Publication of JP2026053355A5 publication Critical patent/JP2026053355A5/ja
Pending legal-status Critical Current

Links

JP2025217417A 2020-03-24 2025-12-02 Tie2結合剤および使用方法 Pending JP2026053355A (ja)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US202062993930P 2020-03-24 2020-03-24
US62/993,930 2020-03-24
US202063046318P 2020-06-30 2020-06-30
US63/046,318 2020-06-30
PCT/US2021/023381 WO2021194913A1 (en) 2020-03-24 2021-03-22 Tie2-binding agents and methods of use
JP2022556535A JP7720317B2 (ja) 2020-03-24 2021-03-22 Tie2結合剤および使用方法
JP2025086919A JP2025138630A (ja) 2020-03-24 2025-05-26 Tie2結合剤および使用方法
JP2025112744A JP2025163021A (ja) 2020-03-24 2025-07-03 Tie2結合剤および使用方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2025112744A Division JP2025163021A (ja) 2020-03-24 2025-07-03 Tie2結合剤および使用方法

Publications (2)

Publication Number Publication Date
JP2026053355A JP2026053355A (ja) 2026-03-25
JP2026053355A5 true JP2026053355A5 (enExample) 2026-04-16

Family

ID=75478286

Family Applications (6)

Application Number Title Priority Date Filing Date
JP2022556535A Active JP7720317B2 (ja) 2020-03-24 2021-03-22 Tie2結合剤および使用方法
JP2025086919A Pending JP2025138630A (ja) 2020-03-24 2025-05-26 Tie2結合剤および使用方法
JP2025112743A Pending JP2025165931A (ja) 2020-03-24 2025-07-03 Tie2結合剤および使用方法
JP2025112744A Pending JP2025163021A (ja) 2020-03-24 2025-07-03 Tie2結合剤および使用方法
JP2025217418A Pending JP2026053356A (ja) 2020-03-24 2025-12-02 Tie2結合剤および使用方法
JP2025217417A Pending JP2026053355A (ja) 2020-03-24 2025-12-02 Tie2結合剤および使用方法

Family Applications Before (5)

Application Number Title Priority Date Filing Date
JP2022556535A Active JP7720317B2 (ja) 2020-03-24 2021-03-22 Tie2結合剤および使用方法
JP2025086919A Pending JP2025138630A (ja) 2020-03-24 2025-05-26 Tie2結合剤および使用方法
JP2025112743A Pending JP2025165931A (ja) 2020-03-24 2025-07-03 Tie2結合剤および使用方法
JP2025112744A Pending JP2025163021A (ja) 2020-03-24 2025-07-03 Tie2結合剤および使用方法
JP2025217418A Pending JP2026053356A (ja) 2020-03-24 2025-12-02 Tie2結合剤および使用方法

Country Status (17)

Country Link
US (3) US11999787B2 (enExample)
EP (1) EP4126949A1 (enExample)
JP (6) JP7720317B2 (enExample)
KR (1) KR20220157445A (enExample)
CN (4) CN120757643A (enExample)
AU (1) AU2021242249A1 (enExample)
BR (1) BR112022018847A2 (enExample)
CA (1) CA3169967A1 (enExample)
CL (1) CL2022002571A1 (enExample)
CO (1) CO2022013937A2 (enExample)
CR (1) CR20220489A (enExample)
IL (1) IL296528A (enExample)
MX (1) MX2022011752A (enExample)
PE (1) PE20230414A1 (enExample)
PH (1) PH12022552267A1 (enExample)
TW (1) TWI901656B (enExample)
WO (1) WO2021194913A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3886946A1 (en) 2019-06-05 2021-10-06 Regeneron Pharmaceuticals, Inc. Devices and methods for precision dose delivery
AU2021242249A1 (en) * 2020-03-24 2022-08-18 Genentech, Inc. Tie2-binding agents and methods of use
KR20250005053A (ko) * 2022-01-13 2025-01-09 인제니아 테라퓨틱스 인크. Vegf 및 tie2-결합 융합 단백질 및 그의 용도
USD1120314S1 (en) 2022-11-30 2026-03-24 Regeneron Pharmaceuticals, Inc. Dose delivery device
WO2025128706A1 (en) * 2023-12-11 2025-06-19 Massachusetts Eye And Ear Infirmary Methods of using tie-2 activators
WO2025178471A1 (ko) * 2024-02-20 2025-08-28 주식회사 맵틱스 Tie2 및 vegf에 특이적으로 결합하는 이중 특이적 항체 및 이의 용도
WO2025198341A1 (ko) * 2024-03-19 2025-09-25 주식회사 파멥신 서로 다른 세포의 Tie2에 트랜스 결합하는 항체 및 이의 용도
CN119569820B (zh) * 2024-12-04 2026-01-30 广西医科大学 一种合浦珠母贝体表粘液抗氧化活性肽及其制备和应用

Family Cites Families (121)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8430252D0 (en) 1984-11-30 1985-01-09 Beecham Group Plc Compounds
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・2・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
EP0368684B2 (en) 1988-11-11 2004-09-29 Medical Research Council Cloning immunoglobulin variable domain sequences.
US5166322A (en) 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
CA2095633C (en) 1990-12-03 2003-02-04 Lisa J. Garrard Enrichment method for variant proteins with altered binding properties
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
US5144088A (en) 1991-04-26 1992-09-01 Aristech Chemical Corporation Manufacture of neopentyl glycol (I)
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
AU2147192A (en) 1991-06-28 1993-01-25 Genentech Inc. Method of stimulating immune response using growth hormone
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
US7018809B1 (en) 1991-09-19 2006-03-28 Genentech, Inc. Expression of functional antibody fragments
FI941572A7 (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenete lmä
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
CA2372813A1 (en) 1992-02-06 1993-08-19 L.L. Houston Biosynthetic binding protein for cancer marker
AU687755B2 (en) 1992-08-21 1998-03-05 Genentech Inc. Method for treating an LFA-1-mediated disorder
EP0679095A1 (en) 1992-11-25 1995-11-02 Amgen Boulder Inc. Modified insulin-like growth factors
AU6626794A (en) 1993-04-07 1994-10-24 Amgen Boulder Inc. Methods of using insulin-like growth factor binding proteins
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
DK0851925T3 (da) 1995-09-21 2005-11-28 Genentech Inc Humane Væksthormonvarianter
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
US7122636B1 (en) 1997-02-21 2006-10-17 Genentech, Inc. Antibody fragment-polymer conjugates and uses of same
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
ES2244066T3 (es) 1997-06-24 2005-12-01 Genentech, Inc. Procedimiento y composiciones de glicoproteinas galactosiladas.
ES2297889T3 (es) 1997-07-14 2008-05-01 Bolder Biotechnology, Inc. Derivados de hormona de crecimiento y proteinas relacionadas.
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
AU759779B2 (en) 1997-10-31 2003-05-01 Genentech Inc. Methods and compositions comprising glycoprotein glycoforms
US6610833B1 (en) 1997-11-24 2003-08-26 The Institute For Human Genetics And Biochemistry Monoclonal human natural antibodies
DK1034298T3 (da) 1997-12-05 2012-01-30 Scripps Research Inst Humanisering af murint antistof
ATE375365T1 (de) 1998-04-02 2007-10-15 Genentech Inc Antikörper varianten und fragmente davon
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
DK1071700T3 (da) 1998-04-20 2010-06-07 Glycart Biotechnology Ag Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet
US6365154B1 (en) 1998-09-28 2002-04-02 Smithkline Beecham Corporation Tie2 agonist antibodies
US6376653B1 (en) 1998-09-28 2002-04-23 Smithkline Beecham Plc Tie2 antagonist antibodies
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
PL209392B1 (pl) 1999-01-15 2011-08-31 Genentech Inc Przeciwciało, komórka gospodarza, sposób wytwarzania przeciwciała oraz zastosowanie przeciwciała
CA2704600C (en) 1999-04-09 2016-10-25 Kyowa Kirin Co., Ltd. A method for producing antibodies with increased adcc activity
ES2248127T3 (es) 1999-10-04 2006-03-16 Medicago Inc. Metodo para regular la transcripcion de genes foraneos en presencia de nigtrogeno.
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
EP1229125A4 (en) 1999-10-19 2005-06-01 Kyowa Hakko Kogyo Kk PROCESS FOR PREPARING A POLYPEPTIDE
EP1240319A1 (en) 1999-12-15 2002-09-18 Genentech, Inc. Shotgun scanning, a combinatorial method for mapping functional protein epitopes
JP2003531588A (ja) 2000-04-11 2003-10-28 ジェネンテック・インコーポレーテッド 多価抗体とその用途
US7064191B2 (en) 2000-10-06 2006-06-20 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
CA2953239A1 (en) 2000-10-06 2002-04-18 Kyowa Hakko Kirin Co., Ltd. Antibody composition-producing cell
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
CA2430013C (en) 2000-11-30 2011-11-22 Medarex, Inc. Transgenic transchromosomal rodents for making human antibodies
NZ571596A (en) 2001-08-03 2010-11-26 Glycart Biotechnology Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
EP1501866A4 (en) 2001-10-02 2006-02-08 Genentech Inc VARIANTS OF THE LIGAND APO-2 AND USES THEREOF
US7521053B2 (en) * 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
CA2463879C (en) 2001-10-25 2012-12-04 Genentech, Inc. Glycoprotein compositions
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
BR0309145A (pt) 2002-04-09 2005-02-01 Kyowa Hakko Kogyo Kk Células das quais o genoma é modificado
EP1500400A4 (en) 2002-04-09 2006-10-11 Kyowa Hakko Kogyo Kk MEDICAMENT WITH ANTIBODY COMPOSITION
CA2481925A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Therapeutic agent for patients having human fc.gamma.riiia
ATE503829T1 (de) 2002-04-09 2011-04-15 Kyowa Hakko Kirin Co Ltd Zelle mit erniedrigter oder deletierter aktivität eines am gdp-fucosetransport beteiligten proteins
CA2481658A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Method of enhancing of binding activity of antibody composition to fcy receptor iiia
EP1498490A4 (en) 2002-04-09 2006-11-29 Kyowa Hakko Kogyo Kk PROCESS FOR PREPARING ANTIBODY COMPOSITION
CA2488441C (en) 2002-06-03 2015-01-27 Genentech, Inc. Synthetic antibody phage libraries
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
KR20040040782A (ko) 2002-11-08 2004-05-13 선바이오(주) 신규한 헥사-암 폴리에틸렌글리콜과 유도체 및 그의합성방법
TWI335821B (en) 2002-12-16 2011-01-11 Genentech Inc Immunoglobulin variants and uses thereof
WO2004065416A2 (en) 2003-01-16 2004-08-05 Genentech, Inc. Synthetic antibody phage libraries
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
JPWO2005035586A1 (ja) 2003-10-08 2007-11-22 協和醗酵工業株式会社 融合蛋白質組成物
JPWO2005035778A1 (ja) 2003-10-09 2006-12-21 協和醗酵工業株式会社 α1,6−フコシルトランスフェラーゼの機能を抑制するRNAを用いた抗体組成物の製造法
US9296820B2 (en) 2003-11-05 2016-03-29 Roche Glycart Ag Polynucleotides encoding anti-CD20 antigen binding molecules with increased Fc receptor binding affinity and effector function
WO2005053742A1 (ja) 2003-12-04 2005-06-16 Kyowa Hakko Kogyo Co., Ltd. 抗体組成物を含有する医薬
EP1740615B1 (en) 2004-03-31 2014-11-05 Genentech, Inc. Humanized anti-tgf-beta antibodies
US7785903B2 (en) 2004-04-09 2010-08-31 Genentech, Inc. Variable domain library and uses
PT1737891E (pt) 2004-04-13 2013-04-16 Hoffmann La Roche Anticorpos anti p-selectina
TWI380996B (zh) 2004-09-17 2013-01-01 Hoffmann La Roche 抗ox40l抗體
DK1791565T3 (en) 2004-09-23 2016-08-01 Genentech Inc Cysteingensplejsede antibodies and conjugates
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
CN101120021A (zh) 2004-12-31 2008-02-06 基因技术公司 结合br3的多肽及其用途
ES2577292T3 (es) 2005-11-07 2016-07-14 Genentech, Inc. Polipéptidos de unión con secuencias hipervariables de VH/VL diversificadas y consenso
EP1973951A2 (en) 2005-12-02 2008-10-01 Genentech, Inc. Binding polypeptides with restricted diversity sequences
TW200812616A (en) 2006-05-09 2008-03-16 Genentech Inc Binding polypeptides with optimized scaffolds
CN101528778A (zh) * 2006-08-18 2009-09-09 埃博灵克斯股份有限公司 用于治疗与il-6-介导的信号传导相关的疾病和病症的针对il-6r的氨基酸序列以及包括其的多肽
WO2008027236A2 (en) 2006-08-30 2008-03-06 Genentech, Inc. Multispecific antibodies
ES2612258T3 (es) 2006-10-27 2017-05-16 Sunnybrook Health Sciences Center Agonistas multiméricos de Tie 2 y usos de los mismos en la estimulación de la angiogénesis
US20080226635A1 (en) 2006-12-22 2008-09-18 Hans Koll Antibodies against insulin-like growth factor I receptor and uses thereof
CN100592373C (zh) 2007-05-25 2010-02-24 群康科技(深圳)有限公司 液晶显示面板驱动装置及其驱动方法
JP6157046B2 (ja) 2008-01-07 2017-07-05 アムジェン インコーポレイテッド 静電的ステアリング(electrostaticsteering)効果を用いた抗体Fcヘテロ二量体分子を作製するための方法
GB2470328A (en) * 2008-03-05 2010-11-17 Ablynx Nv Novel antigen binding dimer complexes, methods of making and uses thereof
US8268314B2 (en) 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
CN101724144A (zh) 2008-11-03 2010-06-09 北京键凯科技有限公司 新型的多臂聚乙二醇及其制备方法和应用
US8133979B2 (en) 2008-12-16 2012-03-13 Hoffmann-La Roche Inc. Antibodies against human angiopoietin 2
BRPI0923810A2 (pt) 2009-01-02 2015-07-14 Alcon Res Ltd Implante oftálmico reabastecido no local
AU2010208046B2 (en) 2009-01-29 2014-10-02 Forsight Vision4, Inc. Posterior segment drug delivery
CN102770456B (zh) 2009-12-04 2018-04-06 弗·哈夫曼-拉罗切有限公司 多特异性抗体、抗体类似物、组合物和方法
US10316105B2 (en) * 2011-08-19 2019-06-11 Regeneron Pharmaceuticals, Inc. Anti-TIE2 antibodies and uses thereof
MX359833B (es) 2011-08-19 2018-10-12 Regeneron Pharma Anticuerpos anti-tie2 y usos de los mismos.
JP6051998B2 (ja) 2012-03-30 2016-12-27 日油株式会社 マルチアーム型ポリエチレングリコール誘導体、その中間体及び製造方法
SG11201408538PA (en) 2012-07-13 2015-02-27 Roche Glycart Ag Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases
JP6699551B2 (ja) * 2014-07-15 2020-05-27 アステラス製薬株式会社 新規抗ヒトTie2抗体
WO2016073157A1 (en) 2014-11-06 2016-05-12 Genentech, Inc. Anti-ang2 antibodies and methods of use thereof
JP6594438B2 (ja) 2014-11-07 2019-10-23 セセン バイオ, インコーポレイテッド 改善されたil−6抗体
US10407510B2 (en) * 2015-10-30 2019-09-10 Genentech, Inc. Anti-factor D antibodies and conjugates
KR20250057128A (ko) * 2015-12-30 2025-04-28 코디악 사이언시스 인코포레이티드 항체 및 이의 접합체
EP3805265A4 (en) * 2018-06-07 2022-07-06 Institute for Basic Science ANTIBODIES BINDING TO TIE2 AND USES THEREOF
WO2019235856A1 (ko) 2018-06-07 2019-12-12 기초과학연구원 Tie2에 결합하는 항체 및 이의 용도
AU2021242249A1 (en) * 2020-03-24 2022-08-18 Genentech, Inc. Tie2-binding agents and methods of use

Similar Documents

Publication Publication Date Title
JP2026053355A5 (enExample)
JP2025138630A5 (enExample)
JP2022061992A5 (enExample)
IL273285B1 (en) Anti- folate receptor alpha antibody conjugates and their uses
JP2023129543A5 (enExample)
HRP20190932T1 (hr) Molekule protutijela koje se vežu na il-17a i il-17f
JP2012521191A5 (enExample)
JP2023178323A5 (enExample)
JP2021516960A5 (enExample)
JP2023166395A5 (enExample)
JP2024167313A5 (enExample)
JP2021159081A5 (enExample)
JP2003527861A5 (enExample)
JP2009517057A5 (enExample)
RU2018130757A (ru) Конъюгаты антитела к cd74, композиции, содержащие конъюгаты антитела к cd74, и способы использования конъюгатов антитела к cd74
JP2024156657A5 (enExample)
HRP20170374T1 (hr) Biološki proizvodi
JP2022512778A5 (enExample)
JP2006506955A5 (enExample)
JP2022516503A5 (enExample)
JP2025183307A5 (enExample)
RU2002105922A (ru) Молекулы антител, обладающие специфичностью в отношении фактора некроза альфа опухоли человека, и их применение
JP2022512234A5 (enExample)
JP2024086870A5 (enExample)
JP2012532851A5 (enExample)